medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 4

<< Back Next >>

Med Int Mex 2022; 38 (4)

Clinical use of neurotropic B vitamins in diseases of the peripheral nervous system in Mexico and Central America

Calderón-Ospina Carlos-Alberto, Franco-González HG, Leal-Martínez F, Orozco-Vázquez AH, Plascencia-Pérez S, Sánchez-Mijangos JH

Language: Spanish
References: 84
Page: 887-902
PDF size: 280.21 Kb.


ABSTRACT

Peripheral neuropathy can be caused by multiple factors and manifest in various symptoms. It is often misdiagnosed if routine or time is lacking, particularly in primary care. Neurotropic B vitamins (B1, B6 and B12) are widely used to improve nerve function. This review summarizes the clinical use of neurotropic B vitamins in the treatment of peripheral neuropathy and B vitamin deficiency in Mexico and Central America and highlights the need of an early diagnosis and treatment of peripheral neuropathy. The content is based on an Advisory Board meeting in Mexico City in 2019 with the aim of better understanding the regional use of high-dose B vitamin products and developing a consensus statement providing guidance for healthcare professionals. Experts from multiple specialties and several Latin American countries, experienced in treating patients with peripheral neuropathy and B vitamin deficiency, gave insights on established regional practices in the treatment of peripheral neuropathy.


REFERENCES

  1. Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy.J Neurol Neurosurg Psychiatry 1997; 62: 310. doi:10.1136/jnnp.62.4.310.

  2. Hughes RAC. Peripheral neuropathy. BMJ 2002; 324: 466-469. doi: 10.1136/bmj.324.7335.466.

  3. Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA. Theepidemiology and risk factors of chronic polyneuropathy.Eur J Epidemiol 2016; 31: 5-20. doi: 10.1007/s10654-015-0094-6.

  4. Amescua-Garcia C, Colimon F, Guerrero C, Jreige IskandarA, Berenguel Cook M, Bonilla P, et al. Most relevant neuropathicpain treatment and chronic low back pain managementGuidelines: A Change Pain Latin America AdvisoryPanel Consensus. Pain Med [Internet]. 2017; 19: 460-470.Available from: https://doi.org/10.1093/pm/pnx198

  5. de Moraes Vieira EB, Garcia JBS, da Silva AAM, MualemAraujo RLT, Jansen RCS. Prevalence, characteristics, andfactors associated with chronic pain with and withoutneuropathic characteristics in Sao Luis, Brazil. J PainSymptom Manage 2012; 44: 239-251. doi: 10.1016/j.jpainsymman.2011.08.014.

  6. Head KA. Peripheral neuropathy: pathogenic mechanismsand alternative therapies. Altern Med Rev 2006; 11:294-329.

  7. International Diabetes Federation. IDF Diabetes Atlas 9thedition, Brussels, 2019 [accessed 9th June 2020].

  8. Rojas-Martínez R, Basto-Abreu A, Aguilar-Salinas CA,Zárate-Rojas E, Villalpando S, Barrientos-Gutiérrez T.Prevalencia de diabetes por diagnóstico médico previoen México. Salud Publica Mex 2018; 60: 224-232. doi:10.21149/8566.

  9. Cardoso MG de M, Weinstock JG, Sardá Júnior JJ. Adhesionto neuropathic pain treatment. Rev Dor 2016; 17: 107-109.DOI 10.5935/1806-0013.20160060.

  10. Román-Pintos LM, Villegas-Rivera G, Rodríguez-CarrizalezAD, Miranda-Díaz AG, Cardona-Muñoz EG. Diabetic polyneuropathy in type 2 diabetes mellitus: inflammation,oxidative stress, and mitochondrial function. J DiabetesRes 2016; 2016: 3425617. doi: 10.1155/2016/3425617.

  11. Parisi MCR, Moura Neto A, Menezes FH, Gomes MB, TeixeiraRM, de Oliveira JEP, et al. Baseline characteristics andrisk factors for ulcer, amputation and severe neuropathy indiabetic foot at risk: the BRAZUPA study. Diabetol MetabSyndr [Internet]. 2016; 8: 25. Available from: https://doi.org/10.1186/s13098-016-0126-8

  12. Ibarra RCT, Rocha LJ, Hernández OR, Nieves R, Leyva JR.Prevalencia de neuropatía periférica en diabéticos tipo 2 enel primer nivel de atención. Rev Méd Chil 2012: 1126-1131.doi: 10.4067/S0034-98872012000900004.

  13. Lazo MLA, Bernabé-Ortiz A, Pinto ME, Ticse R, Malaga G,Sacksteder K, et al. Diabetic peripheral neuropathy in ambulatorypatients with type 2 diabetes in a general hospitalin a middle-income country: a cross-sectional study. PLoSOne 2014; 9:e95403. doi: 10.1371/journal.pone.0095403.

  14. Ubaldo DGJ. Prevalencia de neuropatía periferica en diabetesmellitus. El Dilema la Enseñanza 2013; 27: 10-15.

  15. López JC. Prevalencia de neuropatía periférica en pacientescon diabetes mellitus tipo 2, atendidos en la ClínicaHospital del ISSSTE en Mazatlán, Sinaloa. Rev Esp MédQuir 2011; 16: 71-74.

  16. Ziegler D, Strom A, Lobmann R, Reiners K, Rett K, Schnell O.High prevalence of diagnosed and undiagnosed polyneuropathyin subjects with and without diabetes participatingin a nationwide educational initiative (PROTECT study). JDiabetes Complications 2015; 29: 998-1002. doi: 10.1016/j.jdiacomp.2015.09.008.

  17. Barcelo A, Arredondo A, Gordillo-Tobar A, Segovia J, QiangA. The cost of diabetes in Latin America and the Caribbeanin 2015: Evidence for decision and policy makers. J GlobHealth 2017; 7: 20410. doi: 10.7189/jogh.07.020410.

  18. Barquera S, Campos-Nonato I, Aguilar-Salinas C, Lopez-Ridaura R, Arredondo A, Rivera-Dommarco J. Diabetesin Mexico: cost and management of diabetes and itscomplications and challenges for health policy. GlobalHealth [Internet]. 2013; 9: 3. Available from: https://doi.org/10.1186/1744-8603-9-3.

  19. Arredondo A, De Icaza E. [The cost of diabetes in Latin America:evidence from Mexico]. Value Health [Internet]. 2011;14: S85-88. Available from: https://doi.org/10.1016/j.jval.2011.05.022.

  20. Landmann G. Diagnostik und Therapie der schmerzhaftenPolyneuropathie. Psychiatr Neurol 2012; 5: 13-16.

  21. Rudolph T, Farbu E. Hospital-referred polyneuropathiescauses,prevalences, clinical- and neurophysiological findings.Eur J Neurol 2007; 14: 603-608. doi: 10.1111/j.1468-1331.2007.01758.x.

  22. Hanewinckel R, Drenthen J, van Oijen M, Hofman A,van Doorn PA, Ikram MA. Prevalence of polyneuropathyin the general middle-aged and elderly population.Neurology 2016; 87: 1892-1898. doi: 10.1212/WNL.0000000000003293.

  23. Nold CS, Nozaki K. Peripheral neuropathy: Clinical pearlsfor making the diagnosis. JAAPA 2020; 33: 9-15. doi:10.1097/01.JAA.0000615460.45150.e0.

  24. Johnson PC. Peripheral neuropathy volumes I and II. Editedby PJ, Dyck PK, Thomas EH, Lambert RB, vol I, 1165 pp, volII, 2323 pp, Philadelphia, PA, W. B. Saunders Company,1984. Muscle Nerve [Internet]. John Wiley & Sons, Ltd;1984; 7: 685. Available from: https://doi.org/10.1002/mus.880070818.

  25. Hanewinckel R, Ikram MA, van Doorn PA. Assessment scalesfor the diagnosis of polyneuropathy. J Peripher Nerv Syst2016; 21: 61-73. doi: 10.1111/jns.12170.

  26. Malik RA, Andag-Silva A, Dejthevaporn C, Hakim M, KohJS, Pinzon R, et al. Diagnosing peripheral neuropathy inSouth-East Asia: A focus on diabetic neuropathy. J DiabetesInvestig 2020. doi: 10.1111/jdi.13269.

  27. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, TouboulC. Prevalence of chronic pain with neuropathic characteristicsin the general population. Pain 2008; 136: 380-387.doi: 10.1016/j.pain.2007.08.013.

  28. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B,Bruxelle J, et al. Comparison of pain syndromes associatedwith nervous or somatic lesions and development ofa new neuropathic pain diagnostic questionnaire (DN4).Pain 2005; 114: 29-36. doi: 10.1016/j.pain.2004.12.010.

  29. Adams AS, Callaghan B, Grant RW. Overcoming barriersto diabetic polyneuropathy management in primarycare. Healthcare 2017; 5: 171-173. doi: 10.1016/j.hjdsi.2016.10.003.

  30. Callaghan BC, Kerber K, Smith AL, Fendrick AM, FeldmanEL. The evaluation of distal symmetric polyneuropathy: aphysician survey of clinical practice. Arch Neurol 2012; 69:339-345. doi: 10.1001/archneurol.2011.1735.

  31. Sadosky A, Hopper J, Parsons B. Painful diabetic peripheralneuropathy: results of a survey characterizing theperspectives and misperceptions of patients and healthcarepractitioners. Patient 2014; 7: 107-114. doi: 10.1007/s40271-013-0038-8.

  32. Perkins BA, Olaleye D, Zinman B, Bril V. Simple screeningtests for peripheral neuropathy in the diabetes clinic.Diabetes Care 2001; 24: 250-256. doi: 10.2337/diacare.24.2.250.

  33. Ang GY, Yap CW, Saxena N. Effectiveness of diabetes footscreening in primary care in preventing lower extremityamputations. Ann Acad Med Singapore 2017; 46: 417-423.

  34. American Diabetes Association. Standards of medicalcare in diabetes 2019. Diabetes Care. Am Diabetes Assoc;2019; 42: S1-193.

  35. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, BloomgardenZT, Bush MA, et al. Consensus statement by theAmerican Association of Clinical Endocrinologists andAmerican College of Endocrinology on the comprehensivetype 2 diabetes management algorithm-2017 executivesummary. Endocr Pract 2017; 23: 207-238. doi: 10.4158/EP161682.CS.

  36. Asociación Latinoamericana de Diabetes (ALAD). GuíaDiagnóstico. Control y Tratamiento de la Diabetes Mellitustipo 2 2016; 2: 39-42.

  37. Committee DCCPGE. Diabetes Canada 2018 clinical practiceguidelines for the prevention and management of diabetesin Canada. Can J Diabetes 2018; 42: S1-325.

  38. Vinik AI, Nevoret M-L, Casellini C, Parson H. Diabetic neuropathy.Endocrinol Metab Clin North Am 2013; 42: 747-787.doi: 10.1016/j.ecl.2013.06.001.

  39. Azhary H, Farooq MU, Bhanushali M, Majid A, Kassab MY.Peripheral neuropathy: differential diagnosis and management.Am Fam Physician 2010; 81: 887-892.

  40. Watson JC, Dyck PJB. Peripheral neuropathy: a practicalapproach to diagnosis and symptom management.Mayo Clin Proc 2015; 90: 940-951. doi: 10.1016/j.mayocp.2015.05.004.

  41. Al-Geffari M. Comparison of different screening tests fordiagnosis of diabetic peripheral neuropathy in PrimaryHealth Care setting. Int J Health Sci (Qassim) 2012; 6: 127-134. doi: 10.12816/0005988.

  42. Nazerian P, Volpicelli G, Gigli C, Becattini C, Sferrazza PapaGF, Grifoni S, et al. Diagnostic performance of wells scorecombined with point-of-care lung and venous ultrasoundin suspected pulmonary embolism. Acad Emerg Med 2017;24: 270-280. doi: 10.1111/acem.13130.

  43. Nicholson B, Verma S. Comorbidities in chronic neuropathicpain. Pain Med 2004; 5 Suppl 1: S9-27. doi: 10.1111/j.1526-4637.2004.04019.x.

  44. Finnerup NB, Attal N, Haroutounian S, McNicol E, BaronR, Dworkin RH, et al. Pharmacotherapy for neuropathicpain in adults: a systematic review and meta-analysis.Lancet Neurol 2015; 14: 162-173. doi: 10.1016/S1474-4422(14)70251-0.

  45. Vilar S, Castillo JM, Munuera Martínez P V, Reina M, PabónM. Therapeutic alternatives in painful diabetic neuropathy:a meta-analysis of randomized controlled trials. Korean JPain 2018; 31: 253-260. doi: 10.3344/kjp.2018.31.4.253.

  46. Chawla J, Kvarnberg D. Hydrosoluble vitamins. Handb ClinNeurol 2014, 120: 891-914. doi: 10.1016/B978-0-7020-4087-0.00059-0.

  47. Hernando-Requejo V. Neurological pathology associatedwith vitamin B group deficiency: thiamine, folate and cobalamin.Nutr Hosp 2018; 35: 54-59. doi: 10.20960/nh.2289.

  48. Calderon-Ospina CA, Nava-Mesa MO. B Vitamins in thenervous system: Current knowledge of the biochemicalmodes of action and synergies of thiamine, pyridoxine,and cobalamin. CNS Neurosci Ther 2020; 26: 5-13. doi:10.1111/cns.13207.

  49. Zempleni J, Suttie JW, Gregory III JF, Stover PJ. Handbookof vitamins. 5th edition. CRC Press; 2013.

  50. Dietary reference intakes for thiamin, riboflavin, niacin,vitamin b6, folate, vitamin b12, pantothenic acid, biotin,and choline. Institute of Medicine (US) Standing Committeeon the Scientific Evaluation of Dietary Reference Intakesand its Panel on folate, other b vitamins, and choline.Washington (DC): National Academies Press (US); 1998.

  51. Vanek VW, Borum P, Buchman A, Fessler TA, Howard L,Jeejeebhoy K, et al. ASPEN position paper: recommendationsfor changes in commercially available parenteralmultivitamin and multi-trace element products. Nutr ClinPract 2012; 27: 440-491. doi: 10.1177/0884533612446706.

  52. Cook CCH, Hallwood PM, Thomson AD. B vitamin deficiencyand neuropsychiatric syndromes in alcohol misuse. AlcoholAlcohol 1998; 33: 317-336. doi: 10.1093/oxfordjournals.alcalc.a008400.

  53. Latt N, Dore G. Thiamine in the treatment of Wernickeencephalopathy in patients with alcohol use disorders.Intern Med J [Internet]. 2014; 44: 911-5. Available from:https://doi.org/10.1111/imj.12522

  54. Brown GM, Reynolds JJ. Biogenesis of the water-solublevitamins. Annu Rev Biochem 1963; 32: 419-462. doi:10.1146/annurev.bi.32.070163.002223.

  55. Kennedy DO. B Vitamins and the Brain: Mechanisms,Dose and Efficacy--A Review. Nutrients 2016; 8: 68. doi:10.3390/nu8020068.

  56. Jeon J, Park K. Dietary vitamin B (6) Intake associated witha decreased risk of cardiovascular disease: a prospectivecohort study. Nutrients 2019; 11: 1484. doi: 10.3390/nu11071484.

  57. Spinneker A, Sola R, Lemmen V, Castillo MJ, Pietrzik K,Gonzalez-Gross M. Vitamin B6 status, deficiency and itsconsequences--an overview. Nutr Hosp 2007; 22: 7-24.doi: 10.3390/nu11071484.

  58. European Food Safety Authority. Tolerable upper intakelevels for vitamins and minerals. EFSA J. 2006;1-480. doi:10.2903/j.efsa.2022.e200102.

  59. Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S,Pleasure D, Brown MJ. Sensory neuropathy from pyridoxineabuse. A new megavitamin syndrome. N Engl J Med 1983;309: 445-448. doi: 10.1056/NEJM198308253090801.

  60. Expert Group on Vitamins and Minerals (Institution). EVM00/19/Revised Review of Vitamin B6. 2002.

  61. Lheureux P, Penaloza A, Gris M. Pyridoxine in clinical toxicology:a review. Eur J Emerg Med [Internet]. 2005;12.Available from: https://journals.lww.com/euro-emergencymed/Fulltext/2005/04000/Pyridoxine_in_clinical_toxicology__a_review.7.aspx

  62. McCombe PA, McLeod JG. The peripheral neuropathy ofvitamin B12 deficiency. J Neurol Sci 1984; 66: 117-126. doi:10.1016/0022-510x(84)90147-3.

  63. Reynolds E. Vitamin B12, folic acid, and the nervoussystem. Lancet Neurol 2006; 5: 949-960. doi: 10.1016/S1474-4422(06)70598-1.

  64. Kumar N. Neurologic aspects of cobalamin (B12) deficiency.Handb Clin Neurol 2014; 120: 915-926. doi: 10.1016/B978-0-7020-4087-0.00060-7.

  65. Ortiz-Guerrero G, Amador-Munoz D, Calderon-Ospina CA,Lopez-Fuentes D, Nava Mesa MO. Proton pump inhibitorsand dementia: physiopathological mechanisms and clinicalconsequences. Neural Plast 2018; 2018: 5257285. doi:10.1155/2018/5257285.

  66. Stabler SP. Clinical practice. Vitamin B12 deficiency. N EnglJ Med 2013; 368: 149-160. doi: 10.1056/NEJMcp1113996.

  67. Nilsson-Ehle H. Age-related changes in cobalamin (vitaminB12) handling. Implications for therapy. Drugs Aging 1998;12: 277-292. doi: 10.2165/00002512-199812040-00003.

  68. McCaddon A. Vitamin B12 in neurology and ageing; clinicaland genetic aspects. Biochimie 2013; 95: 1066-1076. doi:10.1016/j.biochi.2012.11.017. Epub 2012 Dec 7.

  69. American Diabetes Association. 1. Improving Care andPromoting Health in Populations: Standards of MedicalCare in Diabetes-2020. Diabetes Care 2020; 43: S7-13. doi:10.2337/dc20-S001.

  70. Leevy CM, Baker H, Tenhove W, Frank O, Cherrick GR.B-complex vitamins in liver disease of the alcoholic. Am JClin Nutr 1965; 16: 339-346. doi: 10.1093/ajcn/16.4.339.

  71. Lanska DJ. The discovery of niacin, biotin, and pantothenicacid. Ann Nutr Metab 2012; 61: 246-253. doi:10.1159/000343115.

  72. Brouwer-Brolsma EM, Dhonukshe-Rutten RAM, vanWijngaarden JP, Zwaluw NL van der, Velde N van der, deGroot LCPGM. Dietary sources of Vitamin B-12 and theirassociation with Vitamin B-12 status markers in healthyolder adults in the B-PROOF Study. Nutrients 2015; 7:7781-7797. doi: 10.3390/nu7095364.

  73. Watanabe F. Vitamin B12 sources and bioavailability. ExpBiol Med 2007; 232: 1266-1274. doi: 10.3181/0703-MR-67.

  74. Okuda K. Discovery of vitamin B12 in the liver and itsabsorption factor in the stomach: A historical review. J GastroenterolHepatol [Internet]. 1999; 14: 301-308. Availablefrom: https://doi.org/10.1046/j.1440-1746.1999.01863.x

  75. Kaushansky K, Kipps TJ. Hematopoietic Agents: GrowthFactors, Minerals, and Vitamins. In: Brunton LL, ChabnerBA, Knollmann BC. eds. Goodman & Gilman's: The PharmacologicalBasis of Therapeutics, 12e. McGraw Hill; 2015.

  76. Vidal‐Alaball J, Butler C, Cannings‐John R, Goringe A, HoodK, McCaddon A, et al. Oral vitamin B12 versus intramuscularvitamin B12 for vitamin B12 deficiency. Cochrane DatabaseSyst Rev 2005;20:CD004655.

  77. Oh R, Brown DL. Vitamin B12 deficiency. Am Fam Physician2003; 67: 979-986.

  78. Sechi G, Sechi E, Fois C, Kumar N. Advances in clinical determinantsand neurological manifestations of B vitamindeficiency in adults. Nutr Rev 2016; 74: 281-300. doi:10.1093/nutrit/nuv107.

  79. Geller M, Oliveira L, Nigri R, Mezitis SG, Ribeiro MG, FonsecaA de S da, et al. B Vitamins for neuropathy and neuropathicpain. Vitam Miner 2017; 6: 2. doi: 10.4172/2376-1318.1000161.

  80. Janka HU, Rietzel S, Mehnert H. Der einfluss von neurobionauf die temperatursensibilität bei patienten mit diabetischerpolyneuropathie. Pharmakologie und KlinischeAnwedung hochdosierter B-Vitamine. Steinkopff-VerlagDarmstadt. Springer; 1991: 87-97.

  81. Rizvi A, Ahmad A, Rizvi Z. Efficacy of combination of VitaminB1, B6, and B12 in management of diabetic peripheralneuropathy. PJMHS 2013; 7: 801-804.

  82. Hakim M, Kurniani N, Pinzon RT, Tugasworo D, Basuki M,Haddani H, et al. Management of peripheral neuropathysymptoms with a fixed dose combination of high-dosevitamin B1, B6 and B12: A 12-week prospective noninterventionalstudy in Indonesia. Asian J Med Sci 2018;9: 32-40. doi.org/10.3126/ajms.v9i1.18510.

  83. Hakim M, Kurniani N, Pinzon RT, Tugasworo D, Basuki M,Haddani H, et al. Vitamin B1, B6, and B12 combination inthe management of peripheral neuropathy symptoms inIndonesia: A sub group analysis of NENOIN Study. J KedoktIndones 2018; 4: 43-49.

  84. Hakim M, Kurniani N, Pinzon RT, Tugasworo D, Basuki M,Haddani H, et al. Subgroup analysis of a 12-week, prospective,non-interventional study of high dose of Vitamin B1,B6 and B12 combination in the management of peripheralneuropathy symptoms in Indonesia. Medika 2018.




2020     |     www.medigraphic.com